Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07678060

Targeting Fronto-Striatal Neural Circuitry Using Repetitive Transcranial Magnetic Stimulation to Reduce Irritability

This pilor study will use repetitive Transcranial Magnetic Stimulation (rTMS) as a noninvasive circuit-based neural modulation to test frontostriatal circuitry as a potential target to reduce irritability.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hartford Healthcare

Hartford, Connecticut, 06102, United States

About this study

Aim 1: To establish frontostriatal (dACC, dlPFC, striatum) circuitry as the neural circuitry mediating frustration.

Aim 2: To modulate the neural circuitry of frustration and evaluate the neural, behavioral, and affective responses.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • able to give informed consent in English
  • elevated levels of irritability, defined as scoring ≥5 on the Affective Reactivity Index (ARI)
  • Absence of cognitive impairment. Must have an IQ equivalent of ≥ 70 on the WASI
  • Absence of MRI or TMS contraindications

Exclusion criteria

  • History of any neurological disorder that would increase seizure risk from rTMS such as stroke, brain lesions, previous neurosurgery, any history of seizure or fainting episode of unknown cause, or head trauma resulting in loss of consciousness, lasting over 30 minutes or with sequela lasting longer than one month.
  • First-degree family history of any neurological disorder with a potentially hereditary basis, including epilepsy or multiple sclerosis.
  • Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps or sensors, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object in the body that precludes rTMS or MRI administration.
  • Current use of any investigational drug or of anti or pro-convulsive action.
  • Use of benzodiazepines.
  • Lifetime history of schizophrenia, bipolar disorder, mania, autism spectrum disorder, intellectual disability, hypomania, or post-traumatic stress disorder.
  • History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack.
  • Participation in any TMS session less than 2 weeks prior to admission. (No TMS exposure for treatment purposes in the last 6 months.)
  • History or current substance use disorder, excluding cannabis use disorder.
  • Major medical illnesses.
  • An acute risk of hurting themselves or others.
  • Pregnant or lactating women.
  • Participant-reported history of severe claustrophobia.
  • Excessive weight beyond the MRI limit (> 450 lbs)

Treatment and study plan

Repetitive transcranial magnetic stimulation (rTMS)

Device

Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. To administer TMS, a stimulator equipped with a figure-8 coil will be used. Two separate coils will be used that are similar in appearance and acoustic properties. One active, unblinded, coil will be used to determine resting motor threshold (RMT) and deliver pulses for the recruitment curves; the other coil will be used to deliver rTMS. rTMS stimulation will be targeted to l-dlPFC.

fMRI

Diagnostic Test

fMRI will be performed pre- and post rTMS

Primary outcomes

  1. Frontostriatal connectivity

    Time frame: Day 1-3

    Frontostriatal connectivity easured using fMRI during a frustration task. The unit of measure is degrees of functional connectivity.

  2. Grip force (an index of motor activity)

    Time frame: Day 1-3

    Grip force measured using a dynamometer during a frustration task. The unit of measure is pounds of force.

  3. Self-reported frustration and unhappiness

    Time frame: Day 1-3

    Self-reported frustration and unhappiness measured using self-rated Likert scales from 1 to 9 during a frustration task. Total score range 1-9 with higher scores indicating more frustration and unhappiness.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Yale Center for Brain and Mind Health

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jul 1, 2026
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.